Brazil has over 14 million people living with type 2 diabetes, yet the most advanced treatments remain out of reach for those depending on the public health system. Here's what you need to know.
The Current Picture of Mounjaro in Brazil
Mounjaro (tirzepatide) received approval from ANVISA, Brazil's health regulatory agency, in 2023 for the treatment of type 2 diabetes. The drug represents a new class of medications called dual GIP/GLP-1 receptor agonists, which work by mimicking two intestinal hormones involved in blood sugar control and appetite regulation.
Despite this approval, tirzepatide remains inaccessible through Brazil's Unified Health System (SUS). Patients who rely on public healthcare can only access this medication through private clinics or pharmacies, at prices that put it well beyond the reach of most Brazilians. At the MounjaBlog, we frequently hear from people wondering when this situation might change.
Where We Stand Today
The Brazilian population dealing with type 2 diabetes is massive. According to VIGITEL surveys and data from the Brazilian Diabetes Society (SBD), millions of Brazilians depend exclusively on SUS for their medications. Currently, the public system offers older GLP-1 options like sitagliptin and liraglutide, but the newer dual-acting receptor agonists have not yet made their way into the public formulary.
The gap between what exists in the private market and what the public system provides continues to widen. Healthcare professionals and patient advocates have pointed out that those who cannot afford private treatment often settle for less effective alternatives, potentially affecting their long-term health outcomes.
How Medication Incorporation Works in SUS
Understanding why Mounjaro is not yet available through SUS requires knowing how the system evaluates new drugs. CONITEC (National Committee for Health Technology Incorporation) is the body responsible for assessing whether new medications should become part of the public healthcare system.
The process involves several stages. Pharmaceutical companies or government bodies submit applications with clinical data, cost-effectiveness analyses, and comparisons against existing treatments. CONITEC then reviews the evidence and opens public consultations where citizens and organizations can share their perspectives. Finally, the committee makes a recommendation to the Ministry of Health.
What Criteria Drive These Decisions
CONITEC evaluates multiple factors when considering a new medication. Clinical effectiveness compared to currently available options is fundamental. The committee also examines cost-effectiveness through metrics like the incremental cost-effectiveness ratio (ICER), which measures how much additional benefit a new drug provides relative to its extra cost. Budget impact analysis is equally important, since incorporating an expensive medication affects how resources get distributed across the entire health system.
The timeline from application to final decision can stretch for years, especially for medications targeting chronic conditions like diabetes, where long-term treatment costs accumulate significantly. At the MounjaBlog, we understand how frustrating this waiting period feels for patients managing their condition every day.
The Cost Challenge: Why Price Remains the Main Barrier
When discussing Mounjaro in the context of SUS, the elephant in the room is price. In the Brazilian private market, monthly supplies of tirzepatide carry costs that represent a substantial portion of minimum wage for many families. Comparing this to other GLP-1 medications like semaglutide (Ozempic) shows that Mounjaro sits at a similar or higher price point, making it one of the more expensive options available.
The budget implications for SUS are considerable. If incorporated, the public system would potentially need to provide this medication to millions of patients. Even with volume-based negotiations, the aggregate cost could strain resources significantly. Other countries have faced similar challenges when attempting to make these innovative medications broadly accessible.
International Experiences and Potential Solutions
Brazil is not alone in grappling with how to balance innovation and affordability. Health technology assessment bodies like the UK's NICE have conducted evaluations of tirzepatide, providing reference points for pricing negotiations. Some countries have explored risk-sharing agreements where payment depends partly on treatment outcomes, or bulk purchasing arrangements that lower per-unit costs.
The possibility of biosimilar versions entering the Brazilian market offers another avenue for reducing costs over time. When generic or biosimilar versions of innovative biologics become available, competition typically drives prices down, which could eventually make broader access more feasible.
Patient Perspectives and Medical Community Input
Patient organizations and the medical community have been vocal about the need for better diabetes medications within SUS. The Brazilian Diabetes Society and other professional groups have highlighted that many patients struggle to achieve adequate glycemic control with currently available options. They point to clinical evidence showing that tirzepatide achieves substantial improvements in HbA1c and body weight compared to older therapies.
The inequality in access is stark. Brazilians with private health insurance or the financial means to pay out of pocket access treatments like Mounjaro, while those dependent on public healthcare work with a more limited toolkit. This disparity affects outcomes and quality of life in ways that concern healthcare professionals across the country.
Advocacy and Public Engagement
Public consultations held by CONITEC represent opportunities for patients, caregivers, and medical professionals to make their voices heard. Advocacy groups have mobilized to submit testimonies and evidence supporting the incorporation of newer diabetes medications. Social media has amplified these efforts, creating spaces where people share experiences and information about accessing treatments.
For those interested in learning more about diabetes management options and staying informed about developments in treatment access, the MounjaBlog offers regular updates and analysis of the Brazilian healthcare landscape.
What Experts Say About the Timeline
Realistic predictions about when tirzepatide might become available through SUS are difficult to make. Based on historical patterns for other innovative chronic disease medications, the process could take several more years. Price negotiations often prove time-consuming, and the Ministry of Health must balance numerous competing priorities when allocating limited resources.
New clinical evidence could influence the timeline. Ongoing cardiovascular outcome studies for tirzepatide may provide additional data that strengthens the case for incorporation. Similarly, if the manufacturer engages proactively with CONITEC and demonstrates flexibility on pricing, progress might accelerate.
The global context matters too. How tirzepatide gets priced and incorporated in other countries affects the leverage Brazil has in its own negotiations. International pressure and the availability of alternatives all factor into the equation.
Options for Patients Today
While waiting for potential incorporation, patients should work closely with their healthcare providers to make the most of available options. Current SUS medications, including older GLP-1 agonists and other diabetes drug classes, remain valuable tools for managing type 2 diabetes. Lifestyle modifications, regular monitoring, and adherence to prescribed treatments continue to make a meaningful difference.
Those with access to private healthcare might discuss with their doctors whether tirzepatide represents an appropriate option given their individual circumstances and health goals.
FAQ
Has CONITEC already evaluated Mounjaro for SUS incorporation?
As of the information available, tirzepatide has not yet been formally evaluated or incorporated into the SUS formulary by CONITEC. The evaluation process typically begins when a manufacturer or government entity submits a formal request.
How long does the medication incorporation process usually take in Brazil?
The timeline varies significantly depending on the medication and available evidence. Complex drugs targeting chronic conditions often take several years from submission to final decision, though expedited pathways exist for certain treatments.
Are there cheaper alternatives to Mounjaro available through SUS?
Yes, SUS currently provides several diabetes medications including older GLP-1 receptor agonists like liraglutide and sitagliptin. While these may be less effective than newer dual agonists for some patients, they remain important options within the public system.
Could future price reductions make Mounjaro more accessible?
Potential future developments like biosimilar versions, international pricing pressure, and negotiated agreements with manufacturers could eventually lower costs. However, no specific timeline for such changes has been announced.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
